Active ingredientTiagabine HClCat. No. P-T106-001CAS 145821-59-6Family · Pharmaceutical analytical standards
Tiagabine
An antiepileptic discovered in Denmark in 1988 that blocks the GAT-1 transporter, increasing the GABA available in the brain; in use since 1997 against partial seizures. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?It derives from nipecotic acid, which blocks GABA reuptake but cannot cross the blood-brain barrier: a lipophilic side chain added to the molecule opens its way into the brain.
Go to the active ingredient →Active ingredientTiagabine HClCat. No. P-T106-001CAS 145821-59-6
Isotopically labelledTiagabine-d6 HydrochlorideCat. No. P-T106-002CAS 1217808-68-8
Impurity(S)-Tiagabine HClCat. No. P-T106-003CAS 145264-34-2
ImpurityTiagabine Impurity 1Cat. No. P-T106-004CAS 1253297-73-2
ImpurityBisthiophenyl methanoneCat. No. P-T106-005CAS 30717-55-6
ImpurityDesmethyl TiagabineCat. No. P-T106-006CAS 745762-44-1
ImpurityTiagabine alcohol analogCat. No. P-T106-007CAS 847233-27-6
ImpurityTiagabine alcohol mesylateCat. No. P-T106-008CAS 847233-13-0
ImpurityTiagabine diolCat. No. P-T106-009CAS 2125725-84-8
ImpurityTiagabine Impurity 2Cat. No. P-T106-010CAS 157925-24-1
ImpurityTiagabine Impurity 3Cat. No. P-T106-011
ImpurityTiagabine Impurity IICat. No. P-T106-012CAS 161014-55-7
ImpurityTiagabine methyl ester ImpurityCat. No. P-T106-013CAS 938158-99-7No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.